Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2000 Jul 24;83(4):438–442. doi: 10.1054/bjoc.2000.1306

A phase II trial of paclitaxel and epirubicin in advanced breast cancer

D Rischin 1, J Smith 2, M Millward 1, C Lewis 3, M Boyer 4, G Richardson 5, G Toner 1, H Gurney 6, J McKendrick 7
PMCID: PMC2374646  PMID: 10945487

Abstract

Initial trials of paclitaxel and doxorubicin in advanced breast cancer yielded high response rates but significant cardiac toxicity was observed. In this phase II trial we investigated the efficacy and safety of paclitaxel combined with epirubicin. Patients with advanced breast cancer, performance status 0–2, measurable disease, and a normal left ventricular ejection fraction, who may have received adjuvant chemotherapy were treated with epirubicin 75 mg m–2followed by a 3-h infusion of paclitaxel 175 mg m–2repeated every 3 weeks. Forty-three eligible patients were treated at six centres. 67% patients received the maximum of six cycles. The response rate was 54% (95% CI 38–69%), 12% CR and 42% PR. Estimated median progression-free survival was 6.9 months (95% CI 5.4–10.0) and estimated median overall survival was 17.9 months (95% CI 14.2–25.7). Four patients had a decrease in the left ventricular ejection fraction (LVEF) of ≥20% of baseline value, and in two patients the LVEF decreased to below the lower limit of normal, but no patient developed clinical evidence of cardiac failure. Grade 4 neutropenia occurred in 56% cycles, but only 4% of cycles were complicated by febrile neutropenia. Grade 3 or 4 non-haematologic toxicity was uncommon. In conclusion, paclitaxel 175 mg m–2and epirubicin 75 mg m–2is a well tolerated, promising regimen for the treatment of advanced breast cancer. © 2000 Cancer Research Campaign

Keywords: taxanes, anthracyclines, breast cancer, phase II

Full Text

The Full Text of this article is available as a PDF (70.3 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Berg S. L., Cowan K. H., Balis F. M., Fisherman J. S., Denicoff A. M., Hillig M., Poplack D. G., O'Shaughnessy J. A. Pharmacokinetics of taxol and doxorubicin administered alone and in combination by continuous 72-hour infusion. J Natl Cancer Inst. 1994 Jan 19;86(2):143–145. doi: 10.1093/jnci/86.2.143. [DOI] [PubMed] [Google Scholar]
  2. Bonadonna G., Gianni L., Santoro A., Bonfante V., Bidoli P., Casali P., Demicheli R., Valagussa P. Drugs ten years later: epirubicin. Ann Oncol. 1993 May;4(5):359–369. doi: 10.1093/oxfordjournals.annonc.a058514. [DOI] [PubMed] [Google Scholar]
  3. Conte P. F., Baldini E., Gennari A., Michelotti A., Salvadori B., Tibaldi C., Danesi R., Innocenti F., Gentile A., Dell'Anna R. Dose-finding study and pharmacokinetics of epirubicin and paclitaxel over 3 hours: a regimen with high activity and low cardiotoxicity in advanced breast cancer. J Clin Oncol. 1997 Jul;15(7):2510–2517. doi: 10.1200/JCO.1997.15.7.2510. [DOI] [PubMed] [Google Scholar]
  4. Conte P. F., Gennari A. Anthracyclines-paclitaxel combinations in the treatment of breast cancer. Ann Oncol. 1997 Oct;8(10):939–943. doi: 10.1023/a:1008208002779. [DOI] [PubMed] [Google Scholar]
  5. Gehl J., Boesgaard M., Paaske T., Vittrup Jensen B., Dombernowsky P. Combined doxorubicin and paclitaxel in advanced breast cancer: effective and cardiotoxic. Ann Oncol. 1996 Sep;7(7):687–693. doi: 10.1093/oxfordjournals.annonc.a010717. [DOI] [PubMed] [Google Scholar]
  6. Gianni L., Munzone E., Capri G., Fulfaro F., Tarenzi E., Villani F., Spreafico C., Laffranchi A., Caraceni A., Martini C. Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol. 1995 Nov;13(11):2688–2699. doi: 10.1200/JCO.1995.13.11.2688. [DOI] [PubMed] [Google Scholar]
  7. Gianni L., Viganò L., Locatelli A., Capri G., Giani A., Tarenzi E., Bonadonna G. Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer. J Clin Oncol. 1997 May;15(5):1906–1915. doi: 10.1200/JCO.1997.15.5.1906. [DOI] [PubMed] [Google Scholar]
  8. Holmes F. A., Madden T., Newman R. A., Valero V., Theriault R. L., Fraschini G., Walters R. S., Booser D. J., Buzdar A. U., Willey J. Sequence-dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer. J Clin Oncol. 1996 Oct;14(10):2713–2721. doi: 10.1200/JCO.1996.14.10.2713. [DOI] [PubMed] [Google Scholar]
  9. Lück H. J., Thomssen C., Du Bois A., Untch M., Lisboa B., Köhler G., Diergarten K. Metastatic breast cancer: experience with the combination paclitaxel plus epirubicin. Oncology (Williston Park) 1998 Jan;12(1 Suppl 1):36–39. [PubMed] [Google Scholar]
  10. Millward M. J., Webster L. K., Rischin D., Stokes K. H., Toner G. C., Bishop J. F., Olver I. N., Linahan B. M., Linsenmeyer M. E., Woodcock D. M. Phase I trial of cremophor EL with bolus doxorubicin. Clin Cancer Res. 1998 Oct;4(10):2321–2329. [PubMed] [Google Scholar]
  11. Rischin D., Webster L. K., Millward M. J., Toner G. C., Nawaratne S., Ganju V., Francis P., Bishop J. F. A phase I and pharmacokinetic study of paclitaxel and epirubicin in advanced cancer. Invest New Drugs. 1999;17(1):73–80. doi: 10.1023/a:1006219601797. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES